EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Asundexian for Secondary Stroke Prevention

Mukul Sharma iD, Qiang Dong, Teruyuki Hirano, Scott E Kasner, Jeffrey L Saver iD, Jaime Masjuan, Andrew M Demchuk, Charlotte Cordonnier, Daniel Bereczki iD, Georgios Tsivgoulis iD, Roland Veltkamp, Ivan Staikov und 43 weitere

New England Journal of Medicine · 16.04.2026 · 394 (15) · 1467-1479

DOI: 10.1056/nejmoa2513880 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 16.04.2026. Verfasst von Mukul Sharma und 54 weiteren Autor:innen. Beteiligte Einrichtung: McMaster University, Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Factor XIa, Ischemic Attack, Transient, Ischemic Stroke, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with noncardioembolic ischemic stroke or transient ischemic attack (TIA) are at risk for recurrent stroke. Low factor XI levels are associated with a reduced risk of ischemic stroke. Asundexian inhibits activated factor XI. Whether the addition of asundexian to antiplatelet therapy would be superior to antiplatelet therapy alone for the secondary prevention of ischemic stroke is unclear. METHODS: In this phase 3, double-blind trial, we randomly assigned patients within 72 hours after the onset of a noncardioembolic ischemic stroke or high-risk TIA to receive asundexian (50 mg once daily) or placebo, in addition to planned dual or single antiplatelet therapy. Patients had at least one of the following: a nonlacunar infarct on imaging, a history of atherosclerosis, or evidence of atherosclerotic plaque at any location on cerebrovascular imaging. The primary efficacy outcome was ischemic stroke. The composite of death from cardiovascular causes, myocardial infarction, or stroke was a key secondary outcome. The primary safety outcome was major bleeding. RESULTS: Among 12,327 patients who underwent randomization (6162 to the asundexian group and 6165 to the placebo group), the incidence of ischemic stroke was lower in the asundexian group than in the placebo group (6.2% vs. 8.4%; cause-specific hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.84; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor XIaIschemic Attack, TransientIschemic StrokePlatelet Aggregation InhibitorsSecondary PreventionAgedFemaleHumansMaleMiddle AgedBenzamidesCardiovascular DiseasesDouble-Blind MethodDrug Therapy, CombinationHemorrhageHydrocarbons, FluorinatedIncidenceKaplan-Meier EstimateMyocardial InfarctionRecurrenceTriazolesTreatment Outcome

Substanzen

asundexianBenzamidesFactor XIaHydrocarbons, FluorinatedPlatelet Aggregation InhibitorsTriazoles

Autor:innen und Institutionen

  • McMaster University, Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada.
  • Department of Neurology, Huashan Hospital Fudan University, Shanghai.
  • Department of Stroke and Cerebrovascular Medicine, Kyorin University School of Medicine, Mitaka, Japan.
  • Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Bayer, Whippany, NJ.
  • University of California, Los Angeles, David Geffen School of Medicine, Los Angeles.

ORCID-Profile: Mukul Sharma, Jeffrey L Saver, Daniel Bereczki, Georgios Tsivgoulis, Hee-Joon Bae, Raed A Joundi, Ashkan Shoamanesh

Förderung

  • Bayer

Zitieren

APA

Sharma, M., Dong, Q., Hirano, T., Kasner, S. E., Saver, J. L., Masjuan, J., Demchuk, A. M., Cordonnier, C., Bereczki, D., Tsivgoulis, G., Veltkamp, R., Staikov, I., Bae, H. J., Campbell, B. C. V., Zini, A., Lee, I. H., Kovar, M., Mikulik, R., Lemmens, R., …, & OCEANIC-STROKE Investigators (2026). Asundexian for Secondary Stroke Prevention. New England Journal of Medicine, 394(15), 1467-1479. https://doi.org/10.1056/nejmoa2513880

Vancouver

Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, et al. Asundexian for Secondary Stroke Prevention. New England Journal of Medicine. 2026;394(15):1467-1479. doi:10.1056/nejmoa2513880

BibTeX
@article{Sharma2026,
  author = {Sharma, Mukul and Dong, Qiang and Hirano, Teruyuki and Kasner, Scott E and Saver, Jeffrey L and Masjuan, Jaime and Demchuk, Andrew M and Cordonnier, Charlotte and Bereczki, Daniel and Tsivgoulis, Georgios and Veltkamp, Roland and Staikov, Ivan and Bae, Hee-Joon and Campbell, Bruce C V and Zini, Andrea and Lee, I-Hui and Kovar, Martin and Mikulik, Robert and Lemmens, Robin and Ferro, José M and Robinson, Thompson and Christensen, Hanne and Ozturk, Serefnur and Leker, Ronen R and Turcani, Peter and Slowik, Agnieszka and Amaya, Pablo and Hoo, Fan Kee and De Marchis, Gian Marco and Knoflach, Michael and Sylaja, P N and Putaala, Jukka and Coutinho, Jonathan M and van der Worp, H Bart and Miglane, Evija and Matijošaitis, Vaidas and Lindgren, Arne G and Sampaio Silva, Gisele and Sandset, Else Charlotte and Turuspekova, Saule T and Amarenco, Pierre and Sheth, Kevin N and Smith, Eric E and Eikelboom, John W and Joundi, Raed A and Schulze, Karleen and Xu, Lizhen and Heenan, Laura and Colorado, Pablo and Keller, Lars and Muehlhofer, Eva and Neumann, Christoph and Mundl, Hardi and Shoamanesh, Ashkan and OCEANIC-STROKE Investigators, OCEANIC-STROKE Investigators},
  title = {Asundexian for Secondary Stroke Prevention},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {15},
  pages = {1467--1479},
  doi = {10.1056/nejmoa2513880}
}
Kostenlos starten →